News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,769 Results
Type
Article (42101)
Company Profile (435)
Press Release (667233)
Section
Business (208981)
Career Advice (2155)
Deals (36013)
Drug Delivery (102)
Drug Development (83488)
Employer Resources (170)
FDA (16412)
Job Trends (15095)
News (353114)
Policy (33087)
Tag
Academia (2631)
Alliances (50877)
Alzheimer's disease (1361)
Approvals (16384)
Artificial intelligence (214)
Bankruptcy (367)
Best Places to Work (11859)
Biotechnology (329)
Breast cancer (231)
Cancer (1759)
Cardiovascular disease (138)
Career advice (1808)
CAR-T (127)
Cell therapy (374)
Clinical research (67043)
Collaboration (698)
Compensation (375)
COVID-19 (2623)
C-suite (168)
Data (1656)
Diabetes (216)
Diagnostics (6355)
Earnings (86950)
Employer resources (147)
Events (114771)
Executive appointments (578)
FDA (17331)
Funding (632)
Gene therapy (266)
GLP-1 (686)
Government (4451)
Healthcare (19138)
Infectious disease (2736)
Inflammatory bowel disease (127)
Interviews (348)
IPO (16755)
Job creations (3706)
Job search strategy (1512)
Layoffs (467)
Legal (7989)
Lung cancer (260)
Manufacturing (244)
Medical device (13440)
Medtech (13445)
Mergers & acquisitions (19626)
Metabolic disorders (580)
Neuroscience (1795)
NextGen: Class of 2025 (6772)
Non-profit (4571)
Northern California (2120)
Obesity (325)
Opinion (212)
Patents (164)
People (58253)
Phase I (21063)
Phase II (29598)
Phase III (21860)
Pipeline (728)
Postmarket research (2600)
Preclinical (8971)
Radiopharmaceuticals (257)
Rare diseases (343)
Real estate (6009)
Regulatory (22412)
Research institute (2411)
Resumes & cover letters (374)
Southern California (1826)
Startups (3756)
United States (18981)
Vaccines (630)
Weight loss (227)
Date
Today (11)
Last 7 days (610)
Last 30 days (2549)
Last 365 days (35488)
2025 (4565)
2024 (36336)
2023 (41057)
2022 (52323)
2021 (56822)
2020 (55017)
2019 (47551)
2018 (35834)
2017 (33114)
2016 (32447)
2015 (38471)
2014 (32255)
2013 (27165)
2012 (29283)
2011 (29936)
2010 (28053)
Location
Africa (737)
Arizona (222)
Asia (38986)
Australia (6489)
California (4887)
Canada (1725)
China (403)
Colorado (221)
Connecticut (242)
Europe (85273)
Florida (692)
Georgia (165)
Illinois (471)
Indiana (262)
Maryland (760)
Massachusetts (3760)
Michigan (205)
Minnesota (340)
New Jersey (1377)
New York (1381)
North Carolina (898)
Northern California (2120)
Ohio (175)
Pennsylvania (1112)
South America (1115)
Southern California (1826)
Texas (717)
Utah (145)
Washington State (485)
709,769 Results for "click therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.
May 22, 2024
·
7 min read
Business
Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn
Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn.
April 1, 2024
·
12 min read
Business
Click Therapeutics and Boehringer Ingelheim Announce FDA Breakthrough Device Designation for Prescription Digital Therapeutic to Treat Negative Symptoms of Schizophrenia
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that the investigational CT-155 prescription digital therapeutic (PDT), co-developed by Boehringer Ingelheim and Click Therapeutics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
January 4, 2024
·
6 min read
Pharm Country
Click Therapeutics Announces Participation in November Investor Conferences
Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, announced that Randall Stanicky, Chief Financial Officer, will participate in the following investor conferences this month.
November 7, 2023
·
1 min read
Pharm Country
Click Therapeutics Announces Participation in Upcoming Technology and Biotechnology Investor Events
Click Therapeutics, Inc., a leader in Digital Therapeutics™ as prescription medical treatments, announced that company management will participate in the following investor events this month.
August 3, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health
Click Therapeutics, Inc. today announced the launch of its second active randomized clinical trial in migraine, ReMMiD-C, Reduction in Monthly Migraine Days-CGRP study, a fully remote and decentralized trial designed to investigate the efficacy and safety of digital therapeutics in reducing the number of monthly migraine days for adults diagnosed with episodic migraine currently receiving Calcitonin-Gene-Related Peptide (CGRP) inhibitor therapy.
August 2, 2023
·
7 min read
Pharm Country
Click Therapeutics Initiates Fully Remote Pivotal Trial Using Investigational Prescription Digital Therapeutics to Treat Episodic Migraine
Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced the initiation of the ReMMi-D, Reduction in Monthly Migraine Days study, a fully remote and decentralized pivotal trial designed to investigate the efficacy and safety of prescription digital therapeutics in reducing the number of monthly migraine days for adults diagnosed with episodic migraine.
April 25, 2023
·
6 min read
Pharm Country
Click Therapeutics Announces Participation in Upcoming Investor Conferences - March 2, 2023
Click Therapeutics, Inc. today announced that company management will participate in two investor conferences this month.
March 2, 2023
·
1 min read
Press Releases
Windtree Therapeutics, Inc. Announces Reverse Stock Split
February 19, 2025
·
7 min read
1 of 70,977
Next
